Human rhinoviruses (HRV) are a common cause of respiratory tract infections (RTI) in hematopoietic SCT (HSCT) patients, although not often associated with severe disease. The clinical spectrum of HRV infection can range from asymptomatic to severe lower RTI and association with post-transplant mortality. [1] [2] [3] [4] [5] [6] [7] HRV have been isolated from the upper and lower respiratory tracts (U/LRT) as sole infecting pathogens and with copathogens. [1] [2] [3] [4] [5] [6] [7] Recently, infection with a newly discovered, genetically distinct HRV, termed HRV type C (HRV-C), has been identified during acute respiratory tract illness in both healthy and immunocompromised children. 8 Data suggest that HRV-C infection can be associated with more severe respiratory illness than infection with other types of HRV. 6, 9 Currently, little is known regarding the incidence, pathogenicity and duration of HRV-C infection in the pediatric HSCT population. We describe a case of persistent LRTI with a single strain of HRV-C in a pediatric HSCT patient with monosomy 7 juvenile myelomonocytic leukemia (JMML).
A 6-month-old boy was diagnosed with JMML and, owing to significant tumor burden, required chemotherapy and decompressive surgery with splenectomy pre-transplant. At the age of 12 months, he underwent reduced intensity allogeneic SCT with fludarabine and melphalan conditioning and 5/6 DRB1 Ag mismatch cord blood. He received tacrolimus and sirolimus for graft-versus-host disease prophylaxis until day 80 post transplant and 4 weeks of IFN starting on day 120 for mixed chimerism.
The patient developed URT symptoms soon after transplant, and a nasal swab on day 21 was positive for HRV by viral panel assay (Luminex, Austin, TX, USA; Table 1 summarizes microbiology test results). During the entire post-transplant course described below, the patient remained negative for all other viruses included in the panel (see Table 1 ). Over the next 2 months, he continued to have intermittent URT symptoms and remained positive for HRV on nasal swab. HRV was detected in a bronchoalveolar lavage (BAL) obtained during an episode of pneumonia on day 78, indicating LRT involvement. This specimen also grew Klebsiella pneumoniae and Enterobacter asbuirae. The pneumonia resolved with antibiotic therapy, but URT symptoms continued. In month 6, he developed a second pneumonia, and a BAL on day 161 was positive for Human Herpes Virus 6 (HHV6). The specimen was not sent for viral panel assay, but a nasal swab obtained 3 days prior (day 158) was positive for HRV. During this time, he developed HHV6 viremia, which resolved with appropriate antiviral therapy. Lower respiratory symptoms persisted, however, and a subsequent nasal swab (day 186) and BAL (day 189) revealed continued presence of HRV in the URT and both HRV and HHV6 in the LRT. In this setting of persistent respiratory infection, the patient relapsed. He received a second myeloablative transplant on day 236 with BU, cyclophosphomide and melphalan conditioning and 5/6 DRB1 Ag mismatch cord blood, with maintenance foscarnet therapy, as transplant was the only curative option.
At day 8 post second transplant, he developed pneumonia (Figure 1) , and a BAL obtained was positive for both HRV and HHV6. His respiratory status deteriorated along with flare up of the HHV6 viremia, which did not respond to foscarnet therapy. Two tracheal aspirates on days 16 and 21 were positive for HHV6 but were not evaluated for the presence of HRV. The aspirate from day 16 also grew Pseudomonas aeruginosa. He died on day 34 post second transplant owing to respiratory failure, renal failure and HHV6 encephalitis.
The patient's respiratory course and multiple HRV-positive specimens prompted a retrospective analysis of available LRT specimens for HRV genotyping. These specimens included three BALs and two tracheal aspirates ( Table 1 ). The specimens were analyzed by conventional PCR with HRV-specific primers P1-1 and P3-1. 10 Analysis of amplicon sequences using NCBI BLAST identified HRV-C genotype 025 (GenBank Accession EF582386) in all five specimens (Table 1) . Unfortunately, owing to differences in sample collection (tracheal aspirate vs BAL) and processing (hospital or KEG's laboratory), accurate estimation of viral load was not possible. These findings indicate persistent LRTI with HRVC-025 for at least 4 months and, when combined with earlier assay results from this patient ( Table 1 ), suggest that HRV-C may have been present in the respiratory tract for nearly the entire duration of the patient's post-transplant course. Although we cannot rule out the possibility of serial infections with other HRV types, previous reports have demonstrated prolonged duration of HRV infections in HSCT patients. 5, 6 In addition, the early onset and duration of HRV infection in this patient are consistent with findings suggesting an inverse correlation between the number of days post transplant at which HRV was detected and duration of infection, 5 as well as longer duration of HRV infection in immunocompromised as compared with otherwise healthy children. 6 Furthermore, immunosuppression and lymphocytopenia near onset of HRV infection have been suggested as risk factors for development of LRTI and may have contributed to the clinical course described above. 3 Studies of HRV-C in pediatric patients suggest more severe pathophysiological sequelae as compared with other HRV types. For example, a prospective study of pediatric asthmatic patients noted that HRV-C infection was associated with higher asthma severity scores than infection with HRV-A or -B. 9 Similarly, Piralla et al 6 noted an increased rate of LRTI with HRV-C in children as compared with adults. Given the presence of co-infecting pathogens in this case, respiratory morbidity cannot be attributed to HRV-C infection alone, and mortality was most likely owing to HHV6 viremia and dissemination. 2, 3 However, HRV infection is often found in the presence of viral co-pathogens and can affect host susceptibility to bacterial superinfection, and thus likely had a significant role in this case. 2 The finding of persistent HRV-C LRTI in a pediatric HSCT patient underscores the need for continued efforts in determining incidence and clinical impact of HRV-C and other HRV types in this patient population. Providing HRV type with viral panel assay results, establishing objective illness severity scores to describe HRV infection, and performing surveillance testing for shedding and carrier states with corresponding viral load data will allow for a more complete characterization of the pathogenic role of HRV-C in children undergoing HSCT. Figure 1 . Chest computed tomography performed 15 days after second transplant, demonstrating bilateral pneumonia.
